Common solutions for heart conditions are just that:  common.  This by no means devalues their importance, nor does it overvalue frequency of use.  In fact, regarding the value proposition, the devices certainly are not inexpensive to implement as a remedy and really should only be used when truly warranted.  Cardiology researcher Dr. Wojcjech Zareba offered expert commentary today on the state of the cardiology today with a specific focus on implantable cardioverter defibrillator …

The granting of a Special Protocol Assessment (“SPA”) by the U.S. Food and Drug Administration is certainly not something to overlook.  According to Wikipedia, a SPA “is a declaration from the Food and Drug Administration that an uncompleted Phase III trial’s design, clinical endpoints, and statistical analyses are acceptable for FDA approval.”  The written agreement from the FDA also covers the scope and size of the patient population, the safety assessments and the …

Inova Technology (OTCBB:INVA) has disclosed some solid financial totals throughout 2011 to this point with announcements of projects being completed valued at $928,000, $515,0000 and $1.4 million (in Q1).  Moreover, releases have contained sprinklings of other information including a backlog of approximately $20 million in work and slashing of debt by roughly $600,000 of debt in February. Today, the Company released contract news revealing that its total contract awards for projects have risen …

Premier Alliance Group, Inc. (OTCBB: PIMO) is a business and technology consulting firm focused on providing solutions for Fortune 2000 companies in the areas of regulatory, compliance, business performance, transformation, and information management. Under the U.S. Bank Secrecy Act (BSA) and certain modifying provisions of the Patriot Act, banking institutions must report daily aggregate transactions in excess of $10,000 for any customer, and suspicious activity appearing to be an attempt to evade the …

Ventrus Biosciences (NASDAQ: VTUS, StockTwits: $VTUS), a company specializing in developing and bringing late-stage prescription drugs to market, with a focus on drugs for gastrointestinal disorders, may get a boost from challenges faced and recently overcome by competitor Uroplasty Inc. (NSDQ: UPI). Uroplasty had fought a lengthy battle to secure third-party reimbursement from regional HMO, PPO, and Medicare insurers, which it recently won. Though the Uroplasty struggle was over its device for urinary …